Literature DB >> 24562930

Basal subtype, as approximated by triple-negative phenotype, is associated with locoregional recurrence in a case-control study of women with 0-3 positive lymph nodes after mastectomy.

A J Khan1, S A Milgrom, N Barnard, S A Higgins, M Moran, Haseeba Shahzad, S Kim, S Goyal, F Al-Faraj, L Kirstein, T Kearney, B G Haffty.   

Abstract

PURPOSE: Basal subtype, as approximated by the triple-negative phenotype (ER-PR-Her2-), has correlated with higher LRR in recent studies. Indications for postmastectomy RT (PMRT) in women with 0-3 positive lymph nodes remain unclear. We evaluated the importance of biologic subtype in a cohort of women with LRR after mastectomy.
METHODS: We identified 22 women with 0-3 positive lymph nodes at our institution who were initially treated with mastectomy (without post-mastectomy radiation), suffered LRRs, and had paraffin-embedded tissue blocks from the primary mastectomy specimen available for staining. None of these women received PMRT. We case-control matched these to 29 women with 0-3 positive nodes who had mastectomy (no PMRT) and remained without evidence of disease at last follow-up and had available primary specimens for processing. We matched controls for age (±3 years) and follow-up duration (<5 year vs. more). Paraffin-embedded specimens were used to construct a triple-redundant tissue microarray. We used conditional logistic regressions to study the association between each predictor and LRR. Results were summarized based on odds ratio (OR).
RESULTS: On univariate analysis, ER+, PR+, or the combination was strongly associated with lower odds of LRR. Basal subtype, as approximated by ER-PR-Her2- (TN), was associated with higher LRR (OR 8.5, p = 0.048). Use of chemotherapy also was associated with lower LRR (OR 0.126, p = 0.0073).
CONCLUSIONS: Our data are concordant with reports from others demonstrating that TN phenotype is associated with higher LRR and can be considered along with other predictors of LRR when selecting women for PMRT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24562930      PMCID: PMC5723128          DOI: 10.1245/s10434-014-3512-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group.

Authors:  R M Clark; T Whelan; M Levine; R Roberts; A Willan; P McCulloch; M Lipa; R H Wilkinson; L J Mahoney
Journal:  J Natl Cancer Inst       Date:  1996-11-20       Impact factor: 13.506

3.  Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.

Authors:  Jianhua Wang; Mei Shi; Rui Ling; Yuesheng Xia; Shanquan Luo; Xuehai Fu; Feng Xiao; Jianping Li; Xiaoli Long; Jianguo Wang; Zengxia Hou; Yunxia Chen; Bin Zhou; Man Xu
Journal:  Radiother Oncol       Date:  2011-08-16       Impact factor: 6.280

4.  Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

Authors:  A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Authors:  Marianne Kyndi; Flemming B Sørensen; Helle Knudsen; Marie Overgaard; Hanne Melgaard Nielsen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

7.  Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.

Authors:  Alphonse Taghian; Jong-Hyeon Jeong; Eleftherios Mamounas; Stewart Anderson; John Bryant; Melvin Deutsch; Norman Wolmark
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

8.  Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group.

Authors:  G Liljegren; L Holmberg; H O Adami; G Westman; S Graffman; J Bergh
Journal:  J Natl Cancer Inst       Date:  1994-05-04       Impact factor: 13.506

9.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

10.  Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.

Authors:  Laura S Dominici; Elizabeth A Mittendorf; Xumei Wang; Jun Liu; Henry M Kuerer; Kelly K Hunt; Abenaa Brewster; Gildy V Babiera; Thomas A Buchholz; Funda Meric-Bernstam; Isabelle Bedrosian
Journal:  Breast Cancer Res       Date:  2012-05-23       Impact factor: 6.466

View more
  2 in total

1.  Risk stratification for prediction of locoregional recurrence in patients with pathologic T1-2N0 breast cancer after mastectomy.

Authors:  Jianyang Wang; Yu Tang; Hao Jing; Guangyi Sun; Jing Jin; Yueping Liu; Yongwen Song; Weihu Wang; Hui Fang; Bo Chen; Shunan Qi; Hua Ren; Ning Li; Yuan Tang; Ningning Lu; Yong Yang; Zihao Yu; Shulian Wang; Yexiong Li
Journal:  BMC Cancer       Date:  2020-11-23       Impact factor: 4.430

2.  Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis.

Authors:  Eduard-Alexandru Bonci; Ștefan Țîțu; Alexandru Marius Petrușan; Claudiu Hossu; Vlad Alexandru Gâta; Morvarid Talaeian Ghomi; Paul Milan Kubelac; Teodora Irina Bonci; Andra Piciu; Maria Cosnarovici; Liviu Hîțu; Alexandra Timea Kirsch-Mangu; Diana Cristina Pop; Ioan Cosmin Lisencu; Patriciu Achimaș-Cadariu; Doina Piciu; Hank Schmidt; Bogdan Fetica
Journal:  Medicina (Kaunas)       Date:  2021-02-26       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.